3 Reasons Netflix Isn't Interested in Advertising
CEO Reed Hastings explains why advertising doesn't make sense for his business.
Editors' Picks
Can Polaris Hitch a Ride With Higher Snowmobile Sales in Q4?
The fourth quarter naturally is a big season for the vehicles.
Do Target-Date Funds Offer Guaranteed Income?
Possibly, but only if you choose the right one.
Why State Street Beat Earnings Estimates
Is the asset management giant a buy?
Recent articles
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
The new drug treats high blood pressure in the lungs.
FDA Approves Merck's Dificid for Infections in Children
The approval includes a new oral suspension version of the drug.
Why SolarEdge Technologies Inc Plunged 12.6% on Monday
An analyst downgrade has this solar stock seeing shadows today.
Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial
The results could help expand use of the drug that's currently approved to treat rheumatoid arthritis.
Medipharm Labs Sues HEXO for Breach of Contract
The dispute is over nearly CA$10 million in unpaid bills stemming from a 2019 supply deal.
Sorrento Therapeutics Rejects Unsolicited Acquisition Offer
The offer undervalued the company, according to the board.
Can Polaris Hitch a Ride With Higher Snowmobile Sales in Q4?
The fourth quarter naturally is a big season for the vehicles.
Why Casino Stocks Are Falling Today
Companies who bet the house on Macau have no way of escaping the coronavirus outbreak.
Why BioCryst Pharmaceuticals Stock Is Jumping Again Today
Rising worries about a deadly virus outbreak are causing the biotech stock to move even higher than it did last week.
Do Target-Date Funds Offer Guaranteed Income?
Possibly, but only if you choose the right one.
Did Facebook Close Out 2019 With a Bang or a Whimper?
The social media giant was a star performer last year, but can it last?
Dow Falls 350 Points as Coronavirus Fears Grow
Markets are starting the week off on a worried note, with major exchanges around the world reporting major losses.
AstraZeneca's Brilinta Beats Aspirin in Trial for Reducing Stroke Chances
Strong late-stage clinical trial results are helping bolster this blood thinner's appeal.
FuelCell Energy Shares Plunge 15.4% as Sell-Off Continues
There's no recovery today for the company's investors.
Is Luckin Coffee's Coronavirus Sell-Off Justified?
The viral outbreak will make it tough for the coffee chain to generate sustainable growth.
Are Nike's Vaporfly Running Shoes "Too Good?"
A decision about the sanctioned use of the popular and controversial shoes by elite runners may be coming later this month.
This Cancer Drug Is Driving Forty Seven's Stock Higher
Positive data from a recent study on its lead compound signifies a turning point for the company and could provide further value for investors.
Is There Room for TiVo in the Platform Wars?
TiVo's new streaming stick platform strategy, unveiled this month at CES, takes aim at Roku and Amazon.
Why State Street Beat Earnings Estimates
Is the asset management giant a buy?
3 Reasons Netflix Isn't Interested in Advertising
CEO Reed Hastings explains why advertising doesn't make sense for his business.